Medical Cannabis Regulation in East and Southeast Asia: A Scoping Review and Policy Insights for Malaysia
Journal of Pharmacy · 31.07.2025 · 5 (2) · 316-329
DOI: 10.31436/jop.v5i2.398 ↗Kurz gefasst
Scoping Review in der Zeitschrift Journal of Pharmacy, online erschienen am 31.07.2025. Verfasst von Fahmi Hassan und 1 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
A global shift towards legalising cannabis for therapeutic use has sparked significant debate in East and Southeast Asia, a region historically defined by stringent anti-narcotics laws. As nations navigate the tension between therapeutic evidence and public health concerns, regulatory responses have diverged, ranging from progressive legalisation to the continuation of strict prohibition.
Methods
This scoping review examines the regulatory frameworks across Indonesia, Malaysia, Thailand, the Philippines, South Korea, Singapore, and Japan to identify divergent models, persistent challenges, and potential policy insights for Malaysia.
Results
The findings reveal a fragmented landscape. Thailand is a regional outlier, having legalised medical cannabis through a controlled system integrating pharmaceutical and traditional medicine. Japan permits only cannabidiol products with negligible tetrahydrocannabinol. Conversely, countries like Indonesia, Singapore, and the Philippines maintain strict prohibition with severe penalties, despite ongoing debates and legislative proposals. This regulatory diversity highlights the tension between public health concerns, economic opportunities, and treaty obligations. For Malaysia, a cautious, incremental policy reform guided by scientific evidence is recommended.
Conclusion
Adopting a regulated CBD-only framework could offer Malaysia a low-risk entry point, balancing therapeutic potential with strict controls. The study underscores the need for evidence-based strategies and stakeholder engagement to facilitate safe patient access while minimising risks of misuse.
Zitieren
APA
Hassan, F., & Zin, R. M. (2025). Medical Cannabis Regulation in East and Southeast Asia: A Scoping Review and Policy Insights for Malaysia. Journal of Pharmacy, 5(2), 316-329. https://doi.org/10.31436/jop.v5i2.398
Vancouver
Hassan F, Zin RM. Medical Cannabis Regulation in East and Southeast Asia: A Scoping Review and Policy Insights for Malaysia. Journal of Pharmacy. 2025;5(2):316-329. doi:10.31436/jop.v5i2.398
BibTeX
@article{Hassan2025,
author = {Hassan, Fahmi and Zin, Rosdi Md},
title = {Medical Cannabis Regulation in East and Southeast Asia: A Scoping Review and Policy Insights for Malaysia},
journal = {Journal of Pharmacy},
year = {2025},
volume = {5},
number = {2},
pages = {316--329},
doi = {10.31436/jop.v5i2.398}
}
EUVIMED